Background {#Sec1}
==========

Extrapulmonary disease accounts for between 10% and 42% of cases of tuberculosis (TB), with the proportion being greater among children and those with immunodeficiency due to HIV co-infection \[[@CR1]\],\[[@CR2]\]. Following haematogenous spread of bacilli during primary pulmonary infection, extrapulmonary TB (EPTB) may later develop in any anatomic location \[[@CR3]\]. Once the diagnosis has been considered, confirmation can be difficult, with sample collection from deep-seated tissues being challenging and the disease typically being paucibacillary. Culture on solid and/or liquid media is the gold standard for diagnosis. However, prolonged turnaround times and limited laboratory infrastructure in resource-limited settings undermine the utility of culture-based diagnosis in clinical practice. Histology is widely used for diagnosis where the technical expertise exists, but this is technically demanding, lacks specificity and is time-consuming \[[@CR4]\]. Existing nucleic acid amplification tests (NAAT) used in high-resource settings have some utility although, to date, have been overly complex to use in most resource-limited settings.

The Xpert MTB/RIF (Xpert) assay (Cepheid Inc., Sunnyvale, CA, USA) is a cartridge-based, semi-automated, rapid molecular assay, which permits rapid TB diagnosis through detection of the DNA of *Mycobacterium tuberculosis* and simultaneous identification of a majority of the mutations that confer rifampicin resistance (which is highly predictive of multi-drug resistant TB \[MDR-TB\]) \[[@CR5]\]. The evidence base regarding the use of Xpert on sputum samples in the diagnosis of pulmonary TB (PTB) in a wide range of high and low-burden settings is strong, with pooled summary estimates of sensitivity when testing smear positive and smear negative samples of 98% (95% CI, 97 -- 99%) and 68% (95% CI, 59 -- 75%), respectively, and a pooled specificity of 98% (95% CI, 97 -- 99%) \[[@CR6]\]. The assay has been CE-marked as compliant with European Union legislation, approved by the United States Federal Drug Administration (FDA) and was first endorsed by the World Health Organization (WHO) in 2010 for use as the initial diagnostic test in individuals suspected of having pulmonary MDR-TB or HIV-associated pulmonary TB \[[@CR7]\]. While the assay is being widely implemented in many high burden countries for this purpose, uncertainty remains concerning its potential role in diagnosis of EPTB \[[@CR8]\]. In addition, the utility of testing non-respiratory samples for the diagnosis of sputum-scarce PTB remains unclear, including gastric aspirate or stool samples in children unable to produce sputum.

An increasing number of studies have now examined the diagnostic accuracy of Xpert for TB diagnosis when testing a wide range of non-respiratory sample types and using a culture-based reference standard. In light of the need to develop/refine global and national guidelines on the use of Xpert when testing non-respiratory samples, this systematic review evaluated and synthesized the available data, taking into account the wide range of different types of samples studied.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

A systematic search of Medline, EMBASE, ISI Web of Science, BIOSIS, Global Health Database, Scopus and Cochrane Database of Systematic Reviews was carried out on 6 November 2013 to identify journal articles and conference abstracts reporting data on the diagnostic accuracy of the Xpert MTB/RIF assay when testing non-respiratory samples. There were no restrictions on study design, patient demographics or whether TB case finding was active or passive. Reference lists of included studies and review articles were hand-searched. The study conformed to the PRISMA statement \[[@CR9]\].

The search strategy is laid out in brief below:

(Free text search terms) "tubercul\*" *OR* "TB" *OR* "MDR-TB" *OR* "XDR-TB" *OR* (Subject heading term) "Tuberculosis"

AND

(Free text search terms) "Xpert" *OR* "MTB/RIF Assay" *OR* "MTB/RIF" *OR* "GeneXpert" *OR* "Cepheid".

Citations were exported into Endnote X7 and duplicates were removed. Two reviewers independently selected titles and abstracts against inclusion and exclusion criteria and the full text of any potentially relevant papers was reviewed.

Eligibility criteria {#Sec4}
--------------------

Eligible studies reported on the diagnostic accuracy of Xpert MTB/RIF for TB when testing non-respiratory clinical samples (specifically excluding sputum, broncho-alveolar lavage fluid, nasopharyngeal aspirates and tracheal aspirates). Studies of both active and passive case finding were included, but those in which samples were selected based on pre-screening with another assay (eg smear microscopy) were excluded. Data reporting on the testing of gastric aspirate and stool samples for diagnosis of pulmonary TB were also included, as were studies examining the utility of testing urine samples to diagnose disseminated TB in HIV-infected patients. Acceptable reference standards were culture of *Mycobacterium tuberculosis* complex on solid and/or liquid media. Studies using other reference standards were excluded. The reference standard for rifampicin resistance was phenotypic drug susceptibility testing (DST).

There were no limits on the number of participants in a study or on the publication date. Studies were excluded if they were not in the English language, if they referred only to respiratory specimens, or if the results of respiratory and non-respiratory specimens were combined and could not be disaggregated. When authors reported studies with duplicated data, only the study with the larger sample size was included.

Data extraction and data analysis {#Sec5}
---------------------------------

Data extraction, verification and study quality assessment were conducted by two of the authors using a standardised data extraction form. The retrieved data included country of study, age-group, gender and HIV status of patients, study setting, types and number of samples tested. The numbers of true positives (tp), true negatives (tn), false positives (fp) and false negatives (fn) were extracted on a *per sample* basis and entered into 2×2 tables. Sensitivity and specificity were calculated from these tables as tp/(tp + fn) and tn/(tn + fp), respectively, with 95% confidence intervals. Since some papers presented data from multiple sample types, multiple estimates were extracted from individual papers. No data were extracted on a per patient basis. In studies which used a composite reference standard, the culture results alone were used as the reference standard.

The primary analyses comprised sensitivity and specificity estimates calculated using all sample types from each paper, but these were disaggregated into two groups according to whether the culture-based reference testing was done on the same sample as the Xpert test or on a different sample. To investigate potential sources of heterogeneity, estimates of sensitivity and specificity were calculated separately for the following sample types: (i) lymph node biopsies and fine needle aspirates; (ii) all tissue types (including lymph node samples); (iii) cerebrospinal fluid (CSF); (iv) pleural fluid samples; and (v) non-pleural serous fluid samples. Additionally estimates were calculated separately for smear positive and smear negative samples and gastric aspirate samples as a method of diagnosing pulmonary tuberculosis. Data were presented on forest plots.

Median values and interquartile ranges (IQRs) for sensitivity and specificity were calculated for the primary analysis and all subanalyses. Pooled estimates of sensitivity and specificity for the analyses by sample type and smear status were calculated in Stata, using the bivariate random effects and random effects models, respectively \[[@CR10]\]. In studies with small numbers of samples, zero events in cells of the 2×2 table, often precluded calculation of pooled estimates of sensitivity/specificity; and in these cases median values and IQRs were calculated. Data on the sensitivity and specificity of Xpert MTB/RIF for detection of rifampicin resistance (compared to phenotypic drug susceptibility) were also examined.

Quality assessment {#Sec6}
------------------

Quality assessment of studies was performed using the QUADAS-2 tool, examining bias and applicability of the studies with respect to four separate domains: patient selection, index test, reference standard and the flow and timing of patients through the study \[[@CR11]\]. No overall summary score was calculated, but for each domain, any concern with regards to bias and applicability were qualified as 'low', 'high' or 'unclear'. These results were then presented in graph and table form.

Results {#Sec7}
=======

Studies included {#Sec8}
----------------

Of a total of 1096 citations, there were 387 unique potentially relevant citations identified and 301 of these were excluded after evaluation of the title and abstract (Figure [1](#Fig1){ref-type="fig"}). Of the remaining 86 papers selected for full text review, 55 papers were subsequently excluded, and 31 papers containing data on the diagnostic accuracy of Xpert MTB/RIF for TB when testing non-respiratory samples were reviewed in detail \[[@CR12]\]-\[[@CR38]\]. Of these, 27 studies published between January 2009 and November 2013 were eligible for inclusion in the qualitative and quantitative synthesis and reported on a total of 6026 non-respiratory samples (Table [1](#Tab1){ref-type="table"}). Four additional studies were excluded on the basis of either using a composite reference standard (n = 2) \[[@CR39]\],\[[@CR40]\], including only samples known to be smear-positive (n = 1) \[[@CR41]\] or providing per patient instead of per sample data (n = 1) \[[@CR42]\] (Additional file [1](#MOESM1){ref-type="media"}: Table S1).Figure 1**Selection of studies reporting on the use of the Xpert MTB/RIF assay for diagnosis of tuberculosis from non-respiratory clinical samples.**

###### 

**Characteristics of included studies**

  First author                            Year          Age (years)                                              \% male   \% HIV   Study setting   Sampling method\*         Gold standard                 Sample types (total n specimens analysed)                                                                                                               Sample used for gold standard                             Composite reference standard included
  --------------------------------------- ------------- -------------------------------------------------------- --------- -------- --------------- ------------------------- ----------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Studies included in meta-analysis**                                                                                                                                                                                                                                                                                                                                                                                       
  **Ablanedo-Terrazas**                   2013          Adults \>16 (Median 29, IQR 24--35.5)                    88.2      100      Clinical        Prospective               Solid and/or liquid culture   Lymph node FNA, lymph node tissue biopsy (68)                                                                                                           As for Xpert                                              N/A
  Mexico                                  Consecutive                                                                                                                                                                                                                                                                                                                                                                         
  **Al-Ateah**                            2012          NR                                                       NR        NR       Laboratory      Prospective               Solid and/or liquid culture   CSF, Tissue/biopsy, Pleural fluid, Lymph node FNA, Pericardial, Peritoneal/ascites fluid, Synovial/articular fluid, Pus/abscess (67)                    As for Xpert                                              N/A
  Saudi Arabia                            Consecutive                                                                                                                                                                                                                                                                                                                                                                         
  **Armand**                              2009          NR                                                       NR        NR       Laboratory      Retrospective             Solid and/or liquid culture   Pleural fluid, Urine, Lymph node, Bone marrow, Pus/abscess\\                                                                                            As for Xpert                                              N/A
  France                                  Convenience                                                                                                                                                                                                                                                                                                                                                                         
  **Bates**                               2011          Children \<15, (Median 20 months, IQR 12 -- 74 months)   NR        30.5     Clinical        Prospective               Liquid culture                Gastric aspirate (788)                                                                                                                                  As for Xpert                                              N/A
  Zambia                                  Consecutive                                                                                                                                                                                                                                                                                                                                                                         
  **Causse**                              2009          Mean 45, Range 5 - 83                                    63.8      NR       Clinical        Prospective               Solid and/or liquid culture   CSF, Tissue/biopsy, Pleural fluid, Gastric aspirate, Pericardial, Peritoneal/ascitic, Synovial/articular, Pus/abscess (340)                             As for Xpert                                              N/A
  Spain                                   Consecutive                                                                                                                                                                                                                                                                                                                                                                         
  **Deggim**                              2010          NR                                                       NR        NR       Laboratory      Prospective               Solid and/or liquid culture   CSF, Tissue/biopsy, Pleural fluid, Peritoneal/ascitic (7)                                                                                               As for Xpert                                              N/A
  Switzerland                             Consecutive                                                                                                                                                                                                                                                                                                                                                                         
  **Feasey**                              2013          Adults only, 37                                          67        100      Clinical        Prospective Unspecified   Solid and/or liquid culture   Blood (104)                                                                                                                                             Sputum and/or blood                                       N/A
  Malawi                                                                                                                                                                                                                                                                                                                                                                                                                      
  **Friedrich**                           2011          NR                                                       NR        NR       Clinical        Prospective Consecutive   Liquid culture                Pleural fluid (25)                                                                                                                                      Sputum and/or Abrams needle biopsy and/or pleural fluid   Culture *and/or* clinical presentation *plus* ADA level *plus* good response to anti-TB treatment
  South Africa                                                                                                                                                                                                                                                                                                                                                                                                                
  **Hanif**                               2009          NR                                                       NR        NR       Laboratory      Prospective               Solid and/or liquid culture   CSF, Pleural fluid, Urine, Gastric aspirate, Pus, Lymph node FNA (29)                                                                                   As for Xpert                                              N/A
  Kuwait                                  Unspecified                                                                                                                                                                                                                                                                                                                                                                         
  **Hillemann**                           2011          NR                                                       NR        NR       Laboratory      Prospective               Solid and/or liquid culture   CSF, Tissue/biopsy, Pleural fluid, Urine, Gastric aspirate, Faeces (521)                                                                                As for Xpert                                              N/A
  Germany                                 Consecutive                                                                                                                                                                                                                                                                                                                                                                         
  **Ioannidis**                           2011          NR                                                       NR        NR       Laboratory      Prospective               Solid and/or liquid culture   CSF, Tissue/biopsy, Pleural fluid, Urine, Lymph node, Gastric aspirate, Pericardial, Synovial/articular, Pus/abscess (39)                               As for Xpert                                              N/A
  Greece                                  Unspecified                                                                                                                                                                                                                                                                                                                                                                         
  **Lawn**                                2012          Adults \>18                                              39.3      100      Clinical        Retrospective             Liquid culture                Urine (168)                                                                                                                                             Sputum                                                    N/A
  South Africa                            Consecutive                                                                                                                                                                                                                                                                                                                                                                         
  **Ligthelm**                            2011          4.2% under 5; 12.5% between 5 and 20; 83.3% over 20      41.6      18.8     Clinical        Prospective               Liquid culture                Lymph node FNA (48)                                                                                                                                     As for Xpert                                              Cytomorphology suggestive of TB with direct visualisation of the organism *and/or* bacterial culture
  South Africa                            Unspecified                                                                                                                                                                                                                                                                                                                                                                         
  **Malbruny**                            2011          Median 52                                                59.8      NR       Laboratory      Prospective               Solid and/or liquid culture   CSF, Tissue/biopsy, Pleural fluid, Urine, Lymph node, Gastric aspirate, Bone marrow, Peritoneal/ascitic fluid, Synovial/articular, Pus/abscess (122)    As for Xpert                                              N/A
  France                                  Unspecified                                                                                                                                                                                                                                                                                                                                                                         
  **Miller**                              2011          NR                                                       NR        NR       Laboratory      Retrospective             Solid and/or liquid culture   NR (23)                                                                                                                                                 As for Xpert                                              N/A
  USA                                     Unspecified                                                                                                                                                                                                                                                                                                                                                                         
  **Moure**                               2011          NR                                                       NR        NR       Laboratory      Retrospective             Liquid culture                CSF, Tissue/biopsy, Pleural fluid, Gastric aspirate, Faeces, Lymph node, Pericardial, Peritoneal/ascitic fluid, Synovial/articular, Pus/abscess (149)   As for Xpert                                              N/A
  Spain                                   Unspecified                                                                                                                                                                                                                                                                                                                                                                         
  **Nhu (a)**                             2013          Children under 16                                        NR        NR       Clinical        Retrospective             Liquid culture                Gastric aspirate (49)                                                                                                                                   As for Xpert                                              Confirmed case (acid-fast bacilli on smear microscopy or positive culture) *or* probable case (clinical symptoms consistent with TB, did not receive an alternative diagnosis and received TB treatment)
  Vietnam                                 Consecutive                                                                                                                                                                                                                                                                                                                                                                         
  **Nhu (b)**                             2013          Adults \>18                                              NR        20.8     Clinical        Prospective               Liquid culture                CSF (379)                                                                                                                                               As for Xpert                                              Culture *and/or* clinical symptoms *and/or* CSF criteria *and/or* cerebral imaging *and/or* evidence TB elsewhere
  Vietnam                                 Consecutive                                                                                                                                                                                                                                                                                                                                                                         
  **Nicol**                               2013          Children \<15 (Median 31 months, IQR 19 -- 57 months)    NR        14.8     Clinical        Prospective               Liquid culture                Stool (115)                                                                                                                                             Sputum                                                    N/A
  South Africa                            Consecutive                                                                                                                                                                                                                                                                                                                                                                         
  **Peter**                               2012          Median 35, IQR 28-38                                     41        100      Clinical        Prospective               Liquid culture                Urine (175)                                                                                                                                             Sputum and/or non-sputum                                  N/A
  South Africa                            Random                                                                                                                                                                                                                                                                                                                                                                              
  **Porcel**                              2013          Mean 50                                                  58        0        Clinical        Prospective               Solid culture                 Pleural fluid (67)                                                                                                                                      As for Xpert                                              Smear *and/or* culture of pleural fluid/sputum; *or* granuloma on pleural biopsy; *or* lymphocytic effusion with increased ADA; *and* resolution of effusion with TB treatment
  Spain                                   Consecutive                                                                                                                                                                                                                                                                                                                                                                         
  **Teo**                                 2011          NR                                                       NR        NR       Laboratory      Unspecified               Solid and/or liquid culture   CSF, Urine, Pleural fluid, Pericardial fluid, Peritoneal/ascitic fluid, Tissue/biopsy, Pus/abscess (31)                                                 As for Xpert                                              N/A
  Singapore                               Unspecified                                                                                                                                                                                                                                                                                                                                                                         
  **Tortoli**                             2012          NR                                                       NR        NR       Laboratory      Retrospective             Solid and/or liquid culture   CSF, Tissue/biopsy, Urine, Pleural fluid, Gastric aspirate, Pus/abscess, Peritoneal, Synovial/articular, Pericardial (1493)                             As for Xpert                                              Culture *and/or* radiological and/or histological signs suggesting TB and improvement after anti-TB treatment
  Italy                                   Consecutive                                                                                                                                                                                                                                                                                                                                                                         
  **Vadwai**                              2011          Median 37, 8 months -- 94 years                          45.9      3        Clinical        Prospective               Solid and/or liquid culture   CSF, Tissue/biopsy, Pleural fluid, Lymph node FNA, Pericardial, Peritoneal/ascitic fluid, Synovial/articular, Pus/abscess (547)                         As for Xpert                                              Confirmed (culture) *or* probable (clinical symptoms, radiological findings and/or histology/cytology suggestive of TB) *or* possible (only clinical symptoms and/or signs suggestive of TB)
  India                                   Consecutive                                                                                                                                                                                                                                                                                                                                                                         
  **Van Rie**                             2013          Aged \>18, Mean 25.8, Range 18 -- 73                     51        100      Clinical        Prospective               Liquid culture                Lymph node FNA (373)                                                                                                                                    As for Xpert                                              Culture *and/or* smear microscopy *and/or* cytology
  South Africa                            Consecutive                                                                                                                                                                                                                                                                                                                                                                         
  **Zeka**                                2011          Median 47.5                                              57.6      NR       Clinical        Prospective               Solid and/or liquid culture   Pleural fluid, Tissue/biopsy, Peritoneal/ascitic fluid, CSF, Pericardial fluid, Urine (176)                                                             As for Xpert                                              Culture *and/or* clinical diagnosis (clinical, pathological and/or radiological findings)
  Turkey                                  Unspecified                                                                                                                                                                                                                                                                                                                                                                         
  **Zmak**                                2013          NR                                                       NR        NR       Laboratory      Prospective               Solid and/or liquid culture   Blood, CSF, Pleural fluid, Urine, Faeces, Pericardial fluid, Peritoneal/ascitic fluid, Tissue/biopsy, Skin swabs (241)                                  As for Xpert                                              N/A
  Croatia                                 Unspecified                                                                                                                                                                                                                                                                                                                                                                         

\*Sample selection: Study units selected prospectively, or retrospectively from existing samples; Consecutive, random or convenience sampling method. 'Unspecified' refers to studies where there was no clear indication how the study participants were chosen.

In the 27 studies included, the number of samples studied ranged between 7 and 1,476, with a median of 115 (IQR, 39 -- 340) (Table [1](#Tab1){ref-type="table"}). Ten studies were from Europe, eight from Africa, seven from Asia and one from both North and Central America. The estimated TB incidence rates in the countries where studies were performed ranged between 3.6/100,000 population/year (USA) to 1003/100,000 population/year (South Africa) in 2012 \[[@CR1]\]. Most studies (20 of 27) were prospective, 6 were retrospective and in one this was unclear. Twelve studies tested samples of only one type, whereas the remaining fifteen studies reported on testing of multiple sample types. The proportion of samples which were culture positive in the studies ranged from 5 -- 100% (Table [1](#Tab1){ref-type="table"}).

Three studies enrolled only children, 5 included only adults, 3 included all age-groups and the remaining 16 studies did not specify participant ages. Patient gender was reported in only 11 studies, with males comprising between 39.3% and 88.2% of participants. Among the 11 studies which reported HIV status, the proportions who were positive ranged between 0% and 100%. Study settings were classified as 'clinical' if patients were recruited to the study (14 studies), and 'laboratory' if samples were selected for inclusion within the laboratory (13 studies).

Methodological quality of included studies {#Sec9}
------------------------------------------

The methodological quality of included studies was assessed using the QUADAS-2 checklist \[[@CR11]\]. A considerable proportion of studies was considered to be at high risk of bias in the patient selection and flow and timing domains (41% and 15% respectively) (Additional file [2](#MOESM2){ref-type="media"}: Figure S1 and Additional file [3](#MOESM3){ref-type="media"}: Figure S2). Within the patient selection domain, studies were considered to be at high risk of bias if a case--control study design was used, or because the study excluded certain groups of patients. The main reason studies were considered at high risk of bias within the flow and timing domain, was because the same reference standard was not used for all patients, or because not all the samples included in the study had been accounted for in the analysis. In 13 of 27 (48%) studies, applicability was considered of high concern with regard to patient selection in the laboratory-based studies.

Overall diagnostic accuracy of Xpert MTB/RIF {#Sec10}
--------------------------------------------

Among the 23 studies comparing Xpert MTB/RIF with culture of the same sample or paired samples obtained from the same anatomic location of disease, the median sensitivity and specificity were 0.83 (IQR, 0.68 -- 0.94; range, 0.25 -- 1.00) and 0.98 (IQR, 0.89 - 1.00; range, 0.73 -- 1.00), respectively (Figure [2](#Fig2){ref-type="fig"}). In contrast, among those studies (n = 4) in which the reference standard included culture of sample types which were different to the non-respiratory sample tested with Xpert (for example, sputum), the median sensitivity of Xpert was much lower (0.22; range 0.19 -- 0.48) \[[@CR18]\],\[[@CR19]\],\[[@CR23]\],\[[@CR30]\],\[[@CR31]\].Figure 2**Sensitivity and specificity of Xpert MTB/RIF assay (A) against culture on same sample type; (B) against culture on different sample types. (A)** Median sensitivity 0.83 (IQR 0.68 -- 0.94), median specificity 0.98 (IQR 0.89 -- 1.00); **(B)** Median sensitivity 0.22 (range 0.19 -- 0.48), median specificity 0.99 (range 0.98 -- 1.00)

Diagnostic accuracy in different sample types for EPTB {#Sec11}
------------------------------------------------------

Disaggregated data were available by sample type for lymph node biopsies and fine needle aspirates, all tissue types (including lymph node samples), cerebrospinal fluid (CSF), pleural fluid and non-pleural serous fluid (pericardial, ascitic and synovial fluid).

The specificity of the Xpert assay was typically very high when used to test samples of all types, with median values of 1.00 for all sample types, including CSF, pleural fluid, non-pleural serous fluid, all tissue samples, lymph node sample and gastric aspirates. Pooled estimates of specificity could not be calculated for CSF or non-pleural serous fluids due to small numbers of samples in these studies, but pooled summary estimates for the remainder ranged from 0.93 to 0.99 (Table [2](#Tab2){ref-type="table"}). The pooled specificity for lymph node tissue (0.93, 95% CI 0.70 - 0.99) was less than that for all tissue samples combined (0.98, 95% CI 0.87 -- 0.99) (Table [2](#Tab2){ref-type="table"}, Figure [3](#Fig3){ref-type="fig"}).Table 2**Sub-analyses of sensitivity and specificity by sample type and smear status**SampleStatistical model for pooled estimatesNumber of studiesSensitivitySpecificityPooled estimate (95% CI)Median (IQR)Pooled estimate (95% CI)Median (IQR)CSFCannot calculate100.85 (0.75 -- 1.00)1.00 (0.98 -- 1.00)Pleural fluidBivariate90.34 (0.24 -- 0.44)0.37 (0.27 -- 0.72)0.98 (0.96 -- 0.99)1.00 (0.98 -- 1.00)Non-pleural serous fluidCannot calculate40.67 (Range 0.00 -- 1.00)1.00 (Range 1.00 -- 1.00)All tissueBivariate120.88 (0.77 -- 0.95)0.90 (0.73 -- 0.99)0.98 (0.87 -- 0.99)1.00 (0.89 -- 1.00)Lymph node biopsy/FNABivariate70.96 (0.72 -- 0.99)0.97 (0.71 -- 1.00)0.93 (0.70 -- 0.99)1.00 (0.94 -- 1.00)Gastric aspirateBivariate80.78 (0.69 -- 0.86)0.85 (0.74 -- 1.00)0.99 (0.98 -- 0.99)1.00 (0.99 -- 1.00)Smear positiveRandom effects90.95 (0.91 -- 1.00)1.00 (0.98 -- 1.00)Smear negativeRandom effects100.69 (0.60 -- 0.80)0.69 (0.61 -- 0.83)Figure 3**Sensitivity and specificity of Xpert MTB/RIF assay in different sample types (A - E).**

In contrast to specificity, sensitivity for TB was very heterogeneous within and between all sample types. Median values for sensitivity ranged from 0.37 -- 0.97. The highest pooled estimate was for lymph node tissue (0.96, 95% CI 0.72 -- 0.99, n = 6), which was lower when all tissue samples were aggregated (0.88, 95% CI 0.77 -- 0.95, n = 11). The lowest pooled sensitivity estimate was that for testing pleural fluid samples (0.34, 95% CI 0.24 -- 0.44, n = 9) (Figure [3](#Fig3){ref-type="fig"}, Table [2](#Tab2){ref-type="table"}).

Diagnostic accuracy in gastric aspirate and stool samples for PTB {#Sec12}
-----------------------------------------------------------------

As shown with other sample types, the specificity of using Xpert to test gastric aspirates for diagnosis of pulmonary TB is extremely high (pooled estimate 0.99, 95% CI 0.98 -- 0.99, range, 0.98 -- 1.00), with a sensitivity pooled estimate of 0.78 (95% CI 0.69 -- 0.86, range, 0.67 -- 1.00) (Figure [4](#Fig4){ref-type="fig"}). Three studies reported on Xpert testing of stool samples compared to culture, but sample sizes were small at 2, 3, and 14 samples per study \[[@CR21]\],\[[@CR27]\],\[[@CR38]\]. The sensitivity in the Hillemann et al. and Moure et al. papers were both 1.00, and the specificity in the Hillemann et al. and Zmak et al. papers were 0.92 and 1.00 respectively (data not shown on forest plot).Figure 4**Sensitivity and specificity of Xpert MTB/RIF assay against a culture reference standard on gastric aspirate samples.**

Two of the gastric aspirate studies were carried out only with children: Bates et al., sensitivity 0.69 (95% CI 0.54 - 0.81), specificity 0.99 \[95% CI 0.98 - 1.00\]; Nhu et al., sensitivity 0.82 (95% CI 0.48 - 0.98), specificity 1.00 (95% CI 0.90 -- 1.00) \[[@CR15]\],\[[@CR29]\]. One further study compared stool samples to culture of sputum in children and found a sensitivity of 0.24 (95% CI 0.07 -- 0.5) \[[@CR30]\]. These results could not be pooled due to the different reference standards between the gastric aspirate studies and the latter study on stool samples. It is likely that the gastric aspirate samples in other studies were collected from children, but age-stratified data were not available and therefore could not be included on an analysis of Xpert MTB/RIF in children.

Association between diagnostic accuracy and smear status and HIV status {#Sec13}
-----------------------------------------------------------------------

Sub-analysis of studies comparing Xpert and culture on smear positive and negative samples was conducted. The sensitivity when testing smear-positive samples (pooled estimate 0.95, 95% CI 0.91 -- 1.00, range 0.92 -- 1.00) far exceeded that observed when testing smear-negative samples (pooled estimate 0.69, 95% CI 0.60 -- 0.80, range 0.38 -- 0.92) (Figure [5](#Fig5){ref-type="fig"}, Table [2](#Tab2){ref-type="table"}). Only one study provided specificity data for smear positive samples, so pooled estimates and comparisons between smear positive and negative samples were not made.Figure 5**Sensitivity of Xpert MTB/RIF assay in (A) smear positive and (B) smear negative samples.**

It was not possible to adequately assess the relationship between HIV status and diagnostic accuracy of Xpert MTB/RIF as only 2 studies provided suitable data. Bates *et al.* studied gastric aspirates from children and found that sensitivity did not differ significantly between HIV negative children (0.74, 95% CI 0.55-0.88) and HIV positive children (0.63, 95% CI 0.36-0.84) \[[@CR15]\]. In contrast, Nicol *et al.* tested stool samples from children and found that the sensitivity in HIV positive children (0.80, 95% CI 0.38-0.96) was substantially higher than that observed in HIV negative children (0.33, 95% CI 0.14-0.61; p-value 0.08) \[[@CR30]\].

Variations in study methodology {#Sec14}
-------------------------------

Study methodology varied greatly across all 27 studies. Sixteen studies used a combination of solid and/or liquid culture as a reference standard, ten studies used only liquid culture and one study used only solid culture (Table [1](#Tab1){ref-type="table"}). Sub-analyses of the pooled estimates for different sample types and smear status by solid or liquid culture were not possible, due to the large number of studies using either solid, or liquid culture, or both.

The methods of studies using CSF and pleural fluid samples were examined to try and establish differences in accuracy when using concentrated and unconcentrated samples. Frequently the methods were not described in sufficient detail (i.e. the volume of fluid used) to allow for sub-analyses on this basis (Additional file [4](#MOESM4){ref-type="media"}: Table S2).

Detection of rifampicin resistance {#Sec15}
----------------------------------

The accuracy of Xpert MTB/RIF for detecting rifampicin resistance compared to phenotypic drug susceptibility testing (DST) was reported for non-respiratory samples in only 6 studies. The total number of samples testing positive for *M. tuberculosis* by Xpert MTB/RIF that were tested by phenotypic DST was 259 and included a variety of sample types (Table [3](#Tab3){ref-type="table"}). However, the prevalence of rifampicin resistance by phenotypic DST in these studies was 0% for those carried out in Europe and sensitivity could not be estimated \[[@CR21]\],\[[@CR27]\],\[[@CR38]\]. The sensitivity for rifampicin resistance was high in the remaining 3 studies from Saudi Arabia (1.00), India (0.98) and South Africa (1.00). Specificity was variable (range, 0.87-1.00).Table 3**Rifampicin resistance detection by Xpert compared to phenotypic drug susceptibility testing**StudyXpert positive samples tested for drug resistance (n)Rifampicin resistance detectionPrevalence of rif resistance by DSTSensitivitySpecificityTPFPFNTNAl-Ateah172001511.7%1.001.00Hillemann26010250%Not estimable0.96Moure63000630%Not estimable1.00Vadwai12539518031.2%0.980.94Zmak12000120%Not estimable1.00*Lawn\*16120136.3%1.000.87*\*Comparison of urine Xpert MTB/RIF vs sputum phenotypic DST.

Indeterminate test results and non-tuberculous mycobacteria {#Sec16}
-----------------------------------------------------------

The proportion of Xpert MTB/RIF indeterminate results was reported by 14 studies, and the median was 1.4% (IQR, 0--4.1%; range 0--26.9%). A high proportion (26.9%) was reported by Feasey *et al.* when testing blood samples. Three studies reported data on non-tuberculous mycobacteria (NTM) identified by culture from 79 samples. Of these, 77 tested negative by Xpert and two had indeterminate results.

Discussion {#Sec17}
==========

In this systematic review, we have carefully evaluated the literature on the diagnostic accuracy of the Xpert MTB/RIF assay when used to test non-respiratory samples and this synthesis supports its use in the diagnosis of both EPTB and sputum-scarce pulmonary TB. The specificity was very high across the majority of studies, highlighting its utility as a rule-in test for TB diagnosis that can be used to reliably inform the start of TB treatment when positive. In contrast, sensitivity was extremely heterogeneous, with much higher sensitivity being typically seen when testing lymph node samples, other tissue samples and cerebrospinal fluid as compared to the results of testing pleural fluid and other serous fluids. These findings strongly support the recently released WHO recommendations for the use of Xpert MTB/RIF for TB diagnosis by testing CSF and tissue samples \[[@CR43]\].

Sensitivity ranged between 0.25 and 1.00 when Xpert and culture were both applied to the index non-respiratory samples. A key source of heterogeneity was the smear-status of samples as previously observed described when testing sputum samples for pulmonary TB diagnosis \[[@CR6]\]. Xpert reliably detected the vast majority of non-respiratory samples testing smear-positive, culture-positive for *M. tuberculosis* but approximately only two-thirds of smear-negative samples. The type of non-respiratory sample tested was another key variable associated with the heterogeneity in sensitivity. Not only were pooled and median sensitivities typically far higher when testing lymph node or other tissue samples and cerebrospinal fluid compared to those observed when testing pleural or other non-pleural serous fluids, but high sensitivity was also observed when testing gastric aspirate samples highlighting an exciting new opportunity in the diagnosis of sputum-scarce pulmonary TB, which is potentially particularly useful in children.

Other potential sources of heterogeneity in sensitivity include small sample sizes, differences in study design, patient selection, patient age (adult versus child) and sample processing methodology. Despite this, high specificity suggests that the Xpert assay could play a useful role as a rapid rule-in test for diagnosis of EPTB, particularly when used to test lymph node samples, tissue biopsies or CSF samples. Limited sensitivity would, however, preclude use of the assay to rule-out EPTB, especially when samples have also been demonstrated to be smear-negative. Collectively, these data suggest that this assay represents an important advance in the diagnosis of EPTB and sputum-scarce pulmonary TB using non-respiratory samples. However, further well-designed, large studies are still needed to definitively characterise the accuracy and impact of this assay, optimum means of obtaining and processing samples.

A systematic review recently published by Denkinger et al., also carefully examined the use of the Xpert assay in extrapulmonary TB \[[@CR44]\]. They searched four databases and included 18 papers with a total of 4461 samples, compared to the 6026 samples from 27 studies included in this review. The review by Denkinger et al. included studies with more than 10 samples of either lymph node tissue, cerebrospinal fluid or pleural fluid, and did not examine the use of non-respiratory samples for diagnosing sputum-scarce pulmonary TB. They examined sensitivity and specificity against both culture and composite reference standards, and for each sample type found that sensitivity increased and specificity decreased against a composite reference standard. We did not compare the findings of Xpert with a composite reference standard since it was evident that this was a further source of substantial heterogeneity since composite reference standards varied so much between studies.

The high pooled estimate of sensitivity we found in smear positive samples (0.96, 95% CI 0.91 -- 1.00) is reflected in the findings by Denkinger et al. (0.97, 95% CI 0.96 -- 0.99). The latter did not analyse smear negative samples, which our study found to have a much lower pooled sensitivity estimate (0.69, 95% CI 0.60 -- 0.80). The very strong association between sample smear status and the sensitivity of Xpert MTB/RIF is entirely consistent with the findings observed when testing sputum samples, reflecting the mycobacterial load present \[[@CR6]\]. In vitro experiments in which sputum samples have been spiked with *M. tuberculosis* have found that the assay retains 95% reliability for detection of the organism in sputum samples spiked with as few as 131 colony forming units per millilitre \[[@CR45]\]. Comparable data are not known for non-respiratory samples types but the threshold for detection may differ according to the degree of polymerase chain reaction (PCR) inhibition associated with various sample types. The Xpert assay will provide an invaluable aid to diagnosis of EPTB in which smears are negative, especially in settings with otherwise limited laboratory capacity. Moreover, for smear-positive samples, Xpert provides a rapid and reliable means of differentiating between *Mycobacterium tuberculosis* complex and non-tuberculous mycobacteria as well as providing a rapid screening for rifampicin-resistance mutations.

We found a higher pooled sensitivity when testing lymph node samples than Denkinger et al. who included data from a larger number of studies (0.96, 95% CI 0.72 -- 0.99, n = 7 compared with 0.83, 95% CI 0.71 -- 0.91, n = 13) \[[@CR44]\]. Several of the studies that we included in the tissue sample group did not describe from which anatomical location the biopsies originated. It is likely that many of the additional data included in that group are also lymph node samples. This may explain why the pooled estimate for all tissue samples in our study is more comparable with the Denkinger et al. findings for lymph node tissue (0.88, 95% CI 0.77 -- 0.95, n = 12) \[[@CR44]\]. Two studies included in our review from South Africa used samples obtained from lymph nodes via fine needle aspiration and reported high sensitivities of 0.93 (Ligthelm *et al.*) \[[@CR24]\] and 0.97 (van Rie *et al.*) \[[@CR36]\], with most of these patients having HIV-coinfection. The very high sensitivities reported are likely to reflect extremely high mycobacterial burden within lymph nodes of these patients and, consistent with this, van Rie *et al.* found that sensitivity was inversely related to blood CD4 cell counts. Ablanedo-Terrazas *et al.* tested both fine needle aspirates and excision biopsies in HIV positive patients, and found sensitivities of 1.00 regardless of the level of immunosuppression \[[@CR12]\]. Denkinger et al. examined whether there was a difference in sensitivity between studies with \>10% HIV positive patients and \<10%, and found that accuracy rates did not differ \[[@CR44]\]. This disparity demonstrates that more work needs to be done to differentiate the impact of HIV on the accuracy of Xpert in tissue samples. As well as HIV-infected patients, children may also benefit from improved diagnosis on lymph node tissue, as up to 50% with extra-thoracic TB have been shown to have cervical lymphadenitis \[[@CR46]\].

TB meningitis (TBM) accounts for approximately 1% of TB disease, but carries a very high mortality risk of between 20% and 50% \[[@CR47]\]. Prognosis worsens with later presentation, which may be exacerbated by prolonged time to diagnosis and treatment initiation. The sensitivity of smear microscopy in some cases can be as low as 20% of culture-confirmed disease, increasing with larger volumes and longer examination times of CSF \[[@CR48]\]. Although culture provides considerably increased sensitivity, prolonged turnaround times mean that initiation of treatment for TBM is frequently empirical. The high median sensitivity of Xpert when testing CSF (0.85, IQR 0.75 -- 1.00) is therefore an important finding, complemented by similar findings by Denkinger et al. (pooled sensitivity 0.81, 95% CI 0.59 -- 0.92) \[[@CR44]\]. One study by Patel *et al*, was excluded from our data synthesis on the basis of its use of a composite reference standard rather than culture alone \[[@CR39]\]. However, a key observation was that testing the pellet from 3 ml of centrifuged CSF provided a sensitivity of 0.65 (95% CI 0.47-0.80) compared to a sensitivity of 0.26 (95% CI 0.17 -- 0.37; p \<0.001) when just 1 ml of uncentrifuged CSF was tested. Denkinger et al. compared concentrated and unconcentrated samples in CSF samples from several studies and also found that sensitivity and specificity were higher in the former group (84.2% vs 51.3%, 98% vs 94.6% respectively) \[[@CR44]\]. The study protocols for all the studies included in this review have been summarised, but there were not sufficient data available to allow for further sub-analyses (Additional file [4](#MOESM4){ref-type="media"}: Table S2).

The lower sensitivities in pleural and non-pleural serous fluid likely reflect the low bacillary burden in these samples. It is known that analysis of pleural biopsies rather than pleural fluid increases microbiological diagnosis as well as allowing histological evaluation \[[@CR49]\]. The study by Christopher *et al.*, which was excluded on the basis of use of composite reference standards, compared the Xpert assay on both pleural fluid and pleural biopsies \[[@CR40]\]. However, this study found no benefit from testing pleural biopsy samples with Xpert. It was frequently unclear from the studies of pleural disease in this review what volumes of pleural fluid were used. As a result of this, sub-analyses on the effect of centrifugation were not carried out as the study methodologies for comparison could not be clearly defined (Additional file [4](#MOESM4){ref-type="media"}: Table S2). Studies in the Denkinger et al. review were found to have higher sensitivities where the proportion of HIV patients was \<10%, and where a concentration step was used, but the paper comments that the confidence intervals are wide and overlapping. Further studies need to define optimum sample volumes for all sterile fluids, processing methodologies and the yield from pleural biopsies.

Missed and delayed diagnosis of TB in children is common, due to non-specific presentation, paucibacillary disease and the difficulty of expectorating sputum \[[@CR50]\]. Two studies specifically sought to test gastric aspirates in children suspected of PTB \[[@CR15]\],\[[@CR29]\], where several other studies incorporated gastric aspirates into a wider study on all sample types with a mixed population. It is likely that the samples from the latter group were also predominantly children. The pooled sensitivity of Xpert on gastric aspirate samples was 0.78 (95% CI 0.68 -- 0.85) compared to 0.25 for smear microscopy in the study by Bates et al. \[[@CR15]\]. Stool samples are another means of testing for pulmonary disease in children, but the sample numbers in the studies included in this review comparing Xpert to culture on stool are very small. Nicol *et al*. compared stool samples to culture of sputum and found a sensitivity of 0.24 (95% CI 0.07 -- 0.5) \[[@CR30]\]. The paucity of age-stratified data in the studies in this review precluded any specific analysis on the use of Xpert MTB/RIF assay in children compared to adults.

Two further studies assessed the utility of Xpert in detecting disseminated disease from urine in HIV-infected out-patients and in-patients, using sputum culture as the reference standard \[[@CR23]\],\[[@CR31]\]. The sensitivity observed among selected sick medical hospital in-patients (0.48; 95% CI 0.38 -- 0.57) \[[@CR31]\] was substantially higher than that observed among unselected ambulatory out-patients undergoing active screening regardless of symptoms prior to starting antiretroviral therapy (0.19; 95% CI 0.11 -- 0.29) \[[@CR23]\]. There was a strong inverse association between Xpert sensitivity and blood CD4 cell count; sensitivity increased to 0.60 in in-patients with CD4 count \<100 cells/ml \[[@CR31]\]. Frequently, such patients are sputum-scarce, preventing the use of sputum smear microscopy, and therefore a rapid test with this sensitivity is critical to those patients who may have high mortality risk while waiting for culture results. Moreover, in combination with another urine rapid test (Determine TB-LAM), a more recent study has shown that sensitivity in this group can be increased further to 0.85 (95% CI 0.75-0.92) \[[@CR51]\]. These results demonstrate that urine-based diagnosis may be particularly useful for routine investigation among HIV-infected medical in-patients.

A paucity of data precludes adequate evaluation of the accuracy of the Xpert assay for detecting rifampicin resistance from non-respiratory samples. The limited data available are similar to those observed when testing sputum samples with high sensitivity but sub-optimal specificity in some studies. However, it should be noted that all these studies were conducted prior to the launch of the modified G4 version of the assay cartridges for which evidence thus far shows much improved specificity in sputum \[[@CR52]\].

Particular strengths of this review include the analysis of non-respiratory samples for diagnosis of PTB, the comprehensive search strategy and comparison of data to a uniform rigorous reference standard. Only five of the original 387 potentially relevant citations from the search needed to be excluded on the basis of language, which is not expected to have significantly altered the result. Stratification of data by sample type revealed the comparative utility of the assay for different forms of EPTB, and complements the meta-analysis by Denkinger et al. \[[@CR44]\]. The findings of the review are limited by differences between studies including study design, clinical populations and patient selection, small sample sizes and non-standardized sample processing. All of these factors may have contributed to the marked degree of heterogeneity observed in the estimates of assay sensitivity. Insufficient data were available to adequately examine certain key variables such as age (adults vs children) and HIV status.

An important unresolved issue regarding the use of Xpert assay to test non-respiratory samples is the differing processing requirements for each sample type. Technical studies on optimum processing methods would enable the highest rates in sensitivity to be achieved, as well as lowering indeterminate rates. Adding in processing steps will mean that use of the assay will likely be restricted to secondary and tertiary care settings potentially limiting the impact of this technology. Larger scale implementation and cost-effectiveness studies should be carried out to identify the true benefits over culture in the time to treatment initiation and subsequent benefits in clinical outcomes. Further studies which allow stratification of data by HIV status or level of immunosuppression may inform how the assay might best be used in active case finding, particularly in areas with high rates of HIV, either alone or in combination with other diagnostic modalities.

Conclusions {#Sec18}
===========

The findings of this review confirm that the Xpert MTB/RIF assay is an important advance in the diagnosis of EPTB and support the WHO guidelines issued by WHO in 2014 \[[@CR43]\]. Principally, Xpert MTB/RIF is likely to be of greatest utility when testing CSF and lymph node or tissue samples, and differentiating tuberculous from non-tuberculous mycobacteria in smear positive samples of any type. In addition, there is clearly a role for testing gastric aspirate samples in diagnosis of sputum-scarce PTB. Further studies are needed to expand the evidence base for use of this assay for diagnosis of EPTB and PTB with different forms of non-respiratory samples in a wide range of clinical populations. However, the present data provide support for current implementation of this assay for EPTB diagnosis.
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